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ABBREVIATIONS OF COMMON TERMS 
AHR: Acute hemodynamic response 
CMR: Cardiac MRI 
CRT: Cardiac Resynchronisation Therapy 
CS: Coronary sinus 
ICM: Ischemic cardiomyopathy 
LBBB: Left bundle branch block 
LV: Left ventricle 
LVEF: Left ventricular ejection fraction 
LVENDO: Left ventricular endocardial 
NICM: Non-ischemic cardiomyopathy 
QLV: The interval between the onset of the QRS complex on the surface ECG to the 
first large positive or negative peak of the LV electrogram during a cardiac cycle. 
 
QRSd: QRS duration 
RV: Right ventricle 
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ABSTRACT 
Introduction: Cardiac resynchronisation therapy (CRT) has emerged as one of the few 
effective treatments for heart failure however, up to 50% of patients derive no benefit. 
Suboptimal LV lead position is a potential cause of poor outcomes whilst targeted lead 
deployment has been associated with enhanced response rates. Image-fusion guidance 
systems represent a novel approach to CRT delivery, allowing physicians to both 
accurately track and target a specific location during LV lead deployment.  
Areas Covered: This review will provide a comprehensive evaluation of how to define 
the optimal pacing site. We will evaluate the evidence for delivering targeted LV 
stimulation at sites displaying favourable viability or advantageous mechanical or 
electrical properties. Finally, we will evaluate several emerging image-fusion guidance 
systems which aim to facilitate optimal site selection during CRT. 
Expert Commentary: Targeted LV lead deployment is associated with reductions in 
morbidity and mortality. Assessment of tissue characterisation and electrical latency are 
critical and can be achieved in a number of ways. Ultimately, the constraints of CS 
anatomy have forced the exploration of novel means of delivering CRT including 
endocardial pacing which hold promise for the future of CRT delivery.  
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1. INTRODUCTION:   
One in five people will suffer from HF during their life time and once diagnosed ~40% of 
patients die within one year[1]. Cardiac resynchronisation therapy (CRT) by pacing the 
left (LV) and right (RV) ventricles to re-coordinate cardiac electrical activation and 
produce a synchronous contraction, has emerged as one of the few effective treatments 
for HF(2,3). However, at present 30% of patients fail to respond clinically through 
improved quality of life, exercise capacity and New York Heart Association (NYHA) 
functional classification of HF and up to 50% show no beneficial changes in cardiac 
function[3]. Suboptimal LV lead position is a common culprit when evaluating poor 
outcomes after CRT [4–7]. Equally, several groups have reported enhanced response 
rates when targeting tissue which displays evidence of favourable viability [8–11] or 
advantageous mechanical [12–18] or electrical [19–23] properties. This review will 
evaluate how to define the optimal LV pacing site and the mechanisms by which it is 
possible to selectively deploy a pacing electrode at this site. 
 
2. ACUTE AND CHRONIC MARKERS OF RESPONSE 
In order to identify the optimal pacing location, it is necessary to perform an examination 
of the available sites and preferentially select the site which possesses the most 
favourable characteristics. Unfortunately, in the 20 years since the first description of 
resynchronisation pacing for heart failure [24], no consensus has been achieved on how 
to define “response” to CRT [25] making comparison of the various pacing sites 
problematic. A multitude of different clinical and event-based definitions of response to 
CRT have been described with rates of response varying from 32% to 91% depending 
on the criteria used. This review will predominantly focus on three indices; outcome 
based metrics which evaluate survival and mortality after device implantation. Markers 
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of left ventricular reverse remodelling (LVRR) following device implantation, of a 
reduction in LV end-systolic volume (LVESV) is the most widely accepted marker 
[26,27]. Finally, some metrics evaluate acute changes in LV contractility. Acute 
haemodynamic response (AHR) is a reproducible marker of LV contractility best 
expressed as the change in the maximum rate of left ventricular pressure (LV-dP/dtmax), 
from a baseline control state [28,29]. Previous work has evaluated the acute 
haemodynamic effects of CRT using LV-dP/dtmax as an outcome measure [29–32] and 
this metric has been used to compare the effects of biventricular pacing at different 
locations [28,29,33]. An improvement in LV-dP/dtmax of 10% during acute implantation 
has been shown to predict chronic LV reverse remodelling in patients receiving CRT 
[34].  
 
3. TISSUE CHARACTERISATION:  
3.1 Pathophysiology of Scar in Ischemic and Non-Ischaemic Cardiomyopathy 
Ischaemic scar forms as a result of permanent myocyte death following an ischaemic 
insult. A reparative process is initiated to rebuild the infarcted myocardium and maintain 
the structural integrity of the ventricle. An initial inflammatory phase of healing is 
followed by a fibrogenic phase that eventually results in the formation of scar tissue as 
dead myocytes are progressively replaced by collagenous scar. Ischaemic scar tends to 
display a sub-endocardial or transmural distribution affecting a specific coronary 
territory. Histological evidence of myocardial fibrosis has also been described in non-
ischaemic presentations [35–37]. Whilst the precise mechanism behind this scar 
formation, which typically follows an epicardial or mid-will distribution, is unclear, 
interstitial and perivascular fibrosis ultimately results in myocardial necrosis [38]. 
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3.2 Impact of scar on the mechanical properties of the heart 
Almost immediately following coronary artery occlusion, the subtended area of 
myocardium becomes passive and non-contractile. The non-viability and reduced 
plasticity of infarcted scar tissue is associated with a reduction in efficient and effective 
mechanical function during systole. Nearly all of the determinants of systolic function 
are negatively impacted by the presence of scar including cardiac shape and 
dimensions, preload, afterload & contractility [39]. During systole, the scared region 
stretches and bulges outward while the remaining myocardium contracts, causing a 
reduction in the mechanical efficiency of the heart as a pump.  This effect is strongly 
dependant on the total area of scared tissue [40]. 
 
3.3 Impact of scar on outcomes 
The size, location and transmurality of scar all impact LV remodelling after CRT. Global 
scar burden has been shown to be inversely proportional to LV reverse remodelling 
amongst both ischaemics [41], non-ischaemics [42] and mixed populations, [43–45]. 
Functional improvement [41,42,46] and survival [47] are also inversely proportional to 
scar burden. Retrospective analysis has confirmed that favourable markers for 
response include smaller scar size and fewer areas of transmural scar [45]. The 
location of scar is of equal importance, in particular when it is located in the postero-
lateral region of the LV, a site empirically thought to be optimal for LV lead deployment. 
Scar in this area is associated with lower response rates following CRT [45,48].  
 
3.4 Impact of scar on electrical activation 
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Scar prevents effective transmission of the electrical impulse, resulting in prolonged 
activation. Electrical activation in regions of fibrosis is characterised by localised delays 
and fractionated, low-amplitude extracellular electrograms [49]. This has been attributed 
to changes in patterns of excitation and conduction due to altered ion channel activity 
[50] and decreased cellular connectivity [51] compounded by tortuous conduction 
though areas of surviving myocytes. This delay in LV activation results in less 
haemodynamic improvement during biventricular pacing [52]. Electrical stimulation in 
regions of scar can also be pro-arrhythmic [53,54] and is associated with increased 
morbidity and mortality [8,55]. Significantly, the presence of myocardial scar at the site 
of LV stimulation during CRT is associated with non-response [8,56]. 
3.5 Scar Identification 
Given the negative implications associated with stimulating scared and fibrotic 
myocardial tissue, current evidence favours avoiding these areas and targeting viable 
tissue. Numerous mechanisms have been proposed in order to differentiate non-viable 
tissue and these can be categorised into anatomical, functional and biological 
modalities, see Table 1. Anatomical imaging involves direct visualisation of tissue 
defined as scarred. Functional imaging relies on surrogate markers of scar such as 
measures of wall motion, strain, voltage or contractile reserve. Biological imaging 
assesses metabolism or perfusion as a surrogate for viability.  
 
3.6 Cardiac MRI 
Late gadolinium enhancement (LGE) cardiac MRI (CMR) is the gold standard for 
delineating myocardial scar with high resolution, as the superior spatial resolution of 
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LGE CMR permits differentiation between epicardial, transmural and sub-endocardial 
infarction. The technique relies on the fact that gadolinium washes out of the blood pool 
but accumulates in the extracellular space. Tissues with weak intracellular bonds and 
high amounts of non-cellular space, including necrotic tissue or fibrous scar, will 
develop higher concentrations of gadolinium than the surrounding healthy tissues. Scar 
detected by LGE CMR has been shown to closely match histologically-proven 
myocardial infarction [57].  
 
3.7 Trans-thoracic echocardiography 
Trans-thoracic echocardiography has the potential to identify areas of scarred or fibrotic 
myocardium. Early work focussed on regional wall thinning [58] and assessment of 
regional contractile function [59] while more recent work has focussed on the ability of 
speckle-tracking radial strain [60] and longitudinal strain [61] to better identify areas of 
regional akinesis. Other techniques include the use of 3D contrast echo [62] and pulse 
cancelation echocardiography [63] which have both shown some promise as tools to 
identify areas of scar.  
3.8 Cardiac Computed Tomography (CT) 
Tissue characterisation using cardiac CT has been used to identify areas of myocardial 
scarring. After an infarct, myocardial tissue replaced by fibrous scar and eventually, 
after several months, undergoes significant lipomatous metaplasia [64]. Using 
unenhanced CT, it is possible to identify the fat in infarcted myocardium. New-
generation dual-source CT (DSCT) allows the integration of late-iodine enhancement 
(LIE) imaging and has been shown to correlate reasonably well (52% sensitivity, 88% 
specificity) with LGE derived CMR imaging [65]. 
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3.9 Nuclear Imaging 
Tracer uptake during Nuclear imaging using either positron emission tomography (PET) 
or single-photon emission computed tomography (SPECT) relies on adequate 
myocardial blood flow and myocyte viability. The finding of a fixed perfusion defect can 
either represent myocardial scar or viable hibernating myocardium. Differentiation 
between these two states can be further enhanced through an assessment of glucose 
uptake via Fluorine-18-labeled deoxyglucose (FDG) with hypocontractile regions 
exhibiting reduced perfusion but normal or increased FDG uptake representing likely 
hibernating myocardium. During head to head comparison, MIBI has been shown to 
consistently overestimate areas of myocardial scar tissue whilst FDG lacks the spatial 
resolution associated with LGE CMR [66].  
 
3.10 Electro-Anatomical Mapping 
Whilst LGE CMR has the capacity to directly visualise anatomic myocardial scar, the 
abnormal electrophysiological substrate extends beyond the dense anatomical scar, 
into regions of heterogeneous “boarder-zone” tissue [67] and may be optimally 
identified using electroanatomic mapping (EAM). The ability of EAM to assess 
myocardial viability on the basis of myocardial voltage has been validated against 
SPECT [68], PET imaging [69] and latterly LGE CMR [70–73] in both ischaemic and 
non-ischaemic cardiomyopathies. Furthermore, analysis of electrogram characteristics 
can also help to predict histologic properties of scar tissue [49].  
 
3.11 Invasive Electroanatomical Mapping 
During invasive EAM, intracardiac electrical activation is recorded in relation to 
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anatomic locations in a particular cardiac chamber of interest, allowing the definition of 
3D cardiac chamber geometry as well as delineating areas of anatomic interest such as 
regions of scar. Systems can be divided into contact and non-contact mapping systems. 
Contact mapping systems rely on recording local activation between two poles on a 
mapping catheter. The resulting bi-polar voltage map can be thresholded to reveal 
areas with a voltage outside of normal range for ventricular tissue, typically 0.5mV to 
1.5mV.  
Non-contact mapping systems utilise a multi-electrode array (MEA) catheter to 
simultaneously record endocardial activation over multiple areas [74]. The array is 
situated on a balloon with 64 electrodes allowing high density mapping from a single 
heartbeat. Advantages of this system include the ability to acquire multiple endocardial 
electrograms during a single cardiac cycle however this comes at the cost of greater 
inaccuracy in electrogram timing and morphology at greater distances from the MEA 
[75]. Work evaluating this system has already established that non-contact mapping can 
identify regions of electrically viable myocardium, which could be used to inform lead 
position, particularly among ischaemic patients [52]. 
 
3.12 Electrocardiographic Imaging 
Electrocardiographic imaging (ECGI) is a novel, non-invasive 3D epicardial 
electrophysiology imaging modality. This technique uses 252 ECG electrodes mounted 
on a wearable vest to reconstruct epicardial potentials from torso potentials, see Figure 
1. These are displayed as electrograms and activation sequences (isochrones) on the 
epicardial surface of the heart [76].  
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ECGI benefits from a non-invasive approach and is able to measure the activation 
across the whole heart simultaneously compared to the slower sequential mapping with 
EAM. Inverse ECG mapping technology is able to identify fibrotic tissue due to the 
abnormal electrical properties exhibited by scarred myocardium, specifically low-
amplitude electrical potentials with broad fractionated electrograms typically in areas 
exhibiting delayed or slow activation [77–79]. A degree of discrepancy between CMR 
and EAM is expected as CMR can struggle to detect areas of homogenous microscopic 
diffuse fibrosis due to the low resolution of the image while inverse ECG EAM can be 
more sensitive at detecting zones of epicardial and transmural fibrosis but may miss 
sub-endocardial scar. Despite this, good correlation has been observed between areas 
of low voltage on ECGI and areas of scar, as identified on LGE CMR [80] with one 
study quoting an 89% sensitivity and 85% specificity at detecting epicardial scar [81]. 
 
4.0 DYSSYNCHRONY ASSESSMENT AND IDENTIFICATION OF THE SITE OF 
LATEST MECHANICAL ACTIVATION (LMA) 
A paradox exists between the electrical substrate corrected by CRT, specifically 
dyssynchronous biventricular electrical activation and its mode of action, which is 
predominately mechanical and aims to enhance cardiac contractility by correcting the 
mechanical dyssynchrony and restoring the mechano-energetic efficiency of the heart. 
Intuitively, it would seem sensible to specifically assess the degree of mechanical 
dyssynchrony present, as this would both help patient selection and aid in the 
determination of the optimal LV pacing site. Dyssynchrony is the measure of dispersion 
in the timing of mechanical contraction of the various LV segments [82] and may be 
measured by a variety of different imaging techniques  
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4.1 Trans-thoracic echocardiography 
Early work assessing the utility of echocardiographic parameters of dyssynchrony to aid 
patient selection for CRT appeared promising. A systolic dyssynchrony index (SDI), 
calculated from tissue Doppler imaging (TDI) proved capable of retrospectively 
predicting enhanced clinical response in single centre work [83]. These benefits were 
also observed in a multicentre retrospective analysis where the use of baseline TDI 
imaging predicted not only functional and echocardiographic improvement but also 
identified patients who yielded prognostic benefit from CRT [84]. Speckle tracking radial 
strain analysis superseded TDI, as it was less dependent on the angle of incidence of 
the ultrasound beam and also appeared able to predict echocardiographic response in 
retrospective analysis [85].  
 
Unfortunately, the utility of mechanical dyssynchrony assessment to identify CRT 
responders has not been reproduced in larger, prospective, randomised multicentre 
studies [86] and this has cast some doubt on the reproducibility of the technique. In 
addition, when all the various echocardiographic measures of mechanical dyssynchrony 
were analysed in a large, international multi-centre study, no single measure proved 
capable of improving patient selection for CRT [87]. Promisingly, newer techniques 
including longitudinal myocardial strain assessment [88] and 3D speckle tracking echo 
[89] appear more reliable and indicate an encouraging direction for future work.  
 
Given the primary target of CRT is the restoration of coordinated myocardial contraction 
and those patients exhibiting mechanical dyssynchrony appeared to yield the most 
benefit from CRT, it seemed logical that the optimal site for LV lead deployment would 
be at the site of maximal mechanical delay. In a retrospective analysis where TDI 
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assessment of mechanical activation was performed prior to CRT implantation, patients 
in whom the LV lead was situated at the site exhibiting the latest activation showed 
increased functional and echocardiographic improvements [15]. Superior response to 
CRT was also observed when the site of latest mechanical activation was targeted 
using tissue synchronization imaging (TSI) [90], 3D echocardiography [91], and speckle 
tracking [92]. The TARGET [13] and STARTER [16] trials prospectively assessed the 
utility of echocardiographic speckle-tracking 2-dimensional radial strain imaging to 
inform LV lead deployment. Echo guided lead implantation was associated with 
echocardiographic response rates (>15% reduction in ESV) of 70% & 57% respectively. 
Both studies showed increased rates of event free survival over empirical lead 
placement.   
 
4.2 Cardiac MRI 
CMR has several potential advantages when looking to characterise mechanical 
activation. These include greater reproducibility, less artefact secondary to patient 
habitus, detailed assessment of myocardial tissue characterisation as well as chamber 
size and volumes and greater spatial resolution. CMR can also assess strain in multiple 
planes allowing the assessment of both radial and longitudinal strain. A recent 
prospective, single-centre randomised study (CMR-CRT) showed the feasibility of 
performing an assessment of circumferential strain in order to identify the latest 
mechanically activated viable segment [93]. Several dyssynchrony assessment metrics 
have been proposed including myocardial tagging, displacement encoding with 
stimulated echoes (DENSE) and phase contrast tissue velocity mapping (TVM). Whilst 
myocardial tag data has been shown to predict functional improvement following CRT 
implantation [94], tag decay remains an issue and this led to the development of 3D 
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volumetric change as a means of assessing both global LV dyssynchrony and 
assessing mechanical activation [95]. When compared to other mechanical 
dyssynchrony measures, volume change systolic dyssynchrony index (SDI) proved the 
sole predictor of chronic reverse remodelling [18].  
 
 
4.3 Cardiac Computed Tomography (CT) 
Cardiac computed tomography (CT) offers a potential benefit over CMR due to the fact 
that approximately 28% of patients undergoing CRT implantation have already received 
an implantable cardiac device rendering them unsuitable to undergo CMR scanning 
[96]. Cardiac CT is associated with submillimetre spatial resolution and can assess 
regional and global LV dyssynchrony by calculating the stretch of the endocardial 
surface throughout the cardiac cycle (stretch quantifier for endocardial engraved zones 
[SQUEEZ]) [97]. When assessed in patients undergoing an upgrade to a CRT pacing 
system, CT-SQUEEZ targets were associated with a similar improvement in AHR as the 
best achievable (20.4% ± 13.7% vs 24.9% ± 11.1%; P=0.36) [98]. In addition, delivering 
LV stimulation at a site identified using CT-SQUEEZ resulted in greater clinical 
response vs non-target segments (90% vs 60%, P < 0.001). 
 
 
5.0 IDENTIFYING THE SITE OF LATEST ELECTRICAL ACTIVATION (LEA) 
The primary substrate targeted during CRT is delayed electrical activation, typically 
manifest by a left bundle branch block pattern on the surface ECG. Detailed analysis of 
ventricular activation confirms a myriad of differing underlying conduction disturbances 
amongst even this group, with ischaemic patients displaying a particularly high degree 
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of variability in activation [99]. The standard 12 lead ECG is therefore of limited use 
when looking to define the optimal site for LV stimulation and focus has shifted to more 
detailed methods of visualising electrical latency. In the context of LBBB, ventricular 
activation is initiated at the distal branching of the right bundle, with activation of the left 
endocardium occurring after a significant delay, as a result of slow conduction through 
the interventricular septum. Theoretically, the site of latest activation should exhibit the 
most dyssynchrony and as such would represent an ideal pacing site. Whilst some work 
appears to confirm the site of LEA is synonymous with the optimal pacing site [21], 
more recent analysis has shown optimal site exhibits late but not supremely delayed 
activation [100]. Sites demonstrating excessively delayed activity may in fact merely 
represent distal activation occurring within islands of non-viable tissue. A variety of 
different methods of identifying the site of latest activation have been described, as 
outlined below.  
5.1 Q-LV & LV Lead Electrical Delay  
An advantage of assessing electrical delay is that it can be performed both intra-
procedurally and without the need for any additional mapping equipment. Singh et al, 
devised a measure of electrical latency called the Left Ventricular Lead Electrical Delay 
(LVLED) [20]. This marker of electrical delay was calculated during LV lead implantation 
by determining the onset of the surface ECG QRS complex to the onset of the sensed 
electrogram on the LV lead, and expressing the value (the Q-LV time) as a percentage 
of the baseline QRS interval. They identified that LVLED correlated with greater 
haemodynamic improvements (derived using transthoracic echo).  
When dichotomised, patients with an LVLED of > 50% exhibited greater event free 
survival and reduced rates of hospitalisation. In a sub-study of the SMART AV Trial 
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[101], patients were again dichotomised, although this time according to the median Q-
LV value (95ms). Gold et al showed that implanting the LV lead at a site with a 
favourable Q-LV was independently associated with symptomatic improvement and 
greater reverse remodelling at 6 months [19]. 
Both of these studies retrospectively analysed the degree of electrical latency at the site 
of LV lead deployment however, Zanon et al evaluated whether Q-LV might be used to 
identify the optimal site in an individual patient by systematically screening all of the 
suitable coronary sinus veins [21]. A strong correlation was observed between Q-LV 
prolongation and improvements in acute haemodynamic response. Again a Q-LV value 
of greater than 95ms appeared significant, yielding an improvement in AHR of >10%, a 
finding which has been associated with predicting long term remodelling [34]. Crucially, 
in 96.8% of patients, the optimal haemodynamic performance was associated with 
delivering pacing therapy at the site exhibiting the latest electrical activation. A similar 
figure (85%) was observed by van Gelder et al in their evaluation of the effects of LV 
endocardial pacing amongst a cohort of non-responders to epicardial CRT [102]. The 
small discrepancy may be attributed to the larger cohort of ischaemic patients in this 
study. 
 
5.2 Narrowing of the Paced QRS  
Reductions in the paced QRSd during biventricular pacing may also aid identification of 
late activating tissue. Widening of the QRS after CRT implantation has been found to be 
an independent predictor of mortality or progression to heart transplantation[103] and 
achieving a reduction in the paced QRS has been shown to predict response in several 
studies [104] including via multi-variate logistic regression [105]. In other work, a 
reduction in paced QRS duration was found to be the only predictor of response [106]. 
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However, this finding is disputed in other studies [107]. There is also no consensus as 
to whether delivering biventricular pacing at a site which achieves a narrowing of the 
paced QRS is associated with improvements in haemodynamics. Whilst some work has 
shown a correlation between narrowing of the QRS and improvements in AHR [100], 
this finding has not been consistently replicated [21]. 
 
5.3 Invasive Electro-Anatomical Mapping 
Electroanatomical mapping has also been used to evaluate electrical activation and 
locate the site of LEA. Analysis of contact and non-contact mapping first data identified 
a “U shaped” pattern of activation during LBBB with depolarisation originating at a 
single septal breakthrough site [99]. Activation could not proceed directly from the 
anterior to the lateral wall, due to the presence of lines of block, forcing the 
depolarisation wave front to pass inferiorly around the apex. Crucially, even amongst 
patients who presented with LBBB on their surface ECG, the location of this line of 
block varied between patients, exposing the heterogeneity of this complex conduction 
disorder and the difficulty in establishing a universal site of LEA. 
More detailed analysis of LV activation revealed heterogeneity in conduction velocities 
in both non-ischaemic and ischaemic patients at the site of LV stimulation in the lateral 
and postero-lateral walls [52]. The location of these areas of slow conduction influenced 
the pattern and direction of wave front propagation. Whilst it was possible to mitigate 
the effects of positioning the lead in an area of slow conduction by altering the timing 
between LV and RV stimulation during CRT; locating and stimulating healthy, late 
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activating tissue was consistently associated with superior haemodynamic 
improvements. 
 
The anatomical constraints of transvenous, epicardial CRT mean that LV stimulation 
can only occur at a site accessible via a tributary of the coronary sinus. Coronary 
venous electroanatomical mapping allows the assessment of electrical latency 
exclusively within the coronary sinus [23]. A high degree of variability in the location of 
the site of LEA was observed between patients. Intra-procedural assessment of latency 
utilising this technique is feasible and whilst of practical value to the implanting 
physician, is limited to only those sites accessible via the available coronary venous 
system.   
 
5.4 Non-Invasive Electro-anatomical mapping of Electrical Activation 
The heterogeneous nature of LV activation in patients with LBBB has also been 
described using ECGi. A key advantage of this technique is the ability to non-invasively 
identify the area of LEA and this approach has already been shown to allow peri-
procedural guidance of the LV lead to the target site. ECGi can also compute an LV 
electrical dyssynchrony index and this metric appears may predict patients likely to 
respond to CRT and aid in identifying the optimal site during LV lead deployment 
[108,109]. 
 
5.5 Correlation between the site of LMA and LEA 
One hypothesis advanced to explain the persistent issue of non-response to CRT is the 
existence of uncoupling of mechanical and electrical synchronicity. Whilst these two 
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substrates can be assessed individually, performing an assessment of both may be 
preferable. Early work appeared to suggest that the site of LEA was synonymous with 
the area of LMA, when evaluated using non-contact EAM and TTE TDI [110]. Similar 
findings were observed when the LMA was assessed using CMR [111]. One 
explanation for this uniformity may be the crucial role played by aetiology and the 
disruptive effects of tissue heterogeneity. The impact of aetiology was better assessed 
by Fujiwara et al who included patients with both ischaemic and non-ischaemic 
cardiomyopathy in their study and identified a clear discrepancy between the site of 
LMA and LEA [112], see Figure 2. Unanimity between the LMA and the LEA site was 
only observed in 19% of patients. 
 
 
5.6 Electrical Activation During RV Pacing & LBBB 
Current class 1 indications for CRT include evidence of dyssynchronous electrical 
activation, manifest on the surface ECG by LBBB. Whilst there has been a great deal of 
focus on characterising the precise nature of LV depolarization which occurs during 
LBBB, activation during CRT occurs as a result of paced stimulation at the LV and 
typically, the RV apex. Whilst an RV paced event appears morphologically similar on 
the surface ECG to conduction resulting from LBBB, Eschalier et al set out to perform a 
more detailed examination. Non-invasive body surface mapping demonstrated clear 
differences in the depolarisation pattern of both the RV and LV during RV pacing and 
LBBB activation. Apical pacing resulted in slower RV conduction with lines of 
conduction detected around the pacing site [113]. LV depolarisation was also observed 
to be prolonged by RV pacing although lines of slow conduction were fewer and shorter 
in size in comparison to those observed during LBBB activation. The LV site of LEA was 
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similar during both RV apical pacing and LBBB activation and was consistently located 
at the LV base. 
 
5.7 Electrical Activation & RV Pacing Site Selection 
 
RV pacing appears to result in delayed LV depolarisation and the deleterious effects of 
RV apical pacing have been widely acknowledged [114,115]. Positioning the RV lead in 
a septal position has been associated with beneficial haemodynamic effects [116]. Early 
work evaluating non-apical RV pacing conducted by Khan et al [117] showed that LV 
remodelling rates were unaffected by RV lead position while Kutyifa et al [118] also  
highlighted a higher risk of ventricular arrhythmias. The SEPTAL CRT study randomly 
assigned patients to receive either an septal or apical RV lead and demonstrated no 
significant difference in clinical outcome [119].  
 
It is worth noting that there is little consensus on a universal optimal site of LV lead 
deployment and instead an individualised approach which takes into account aetiology, 
tissue characterisation and the underlying electrical substrate appears to yield the 
greatest benefit [120]. Similarly, patient specific RV lead placement may represent a 
superior strategy, particularly when faced with limited viable LV pacing sites due to the 
anatomical constraints associated with transvenous, epicardial CRT. In a pilot study of 
seven patients, Kumar et al observed that patient specific RV lead placement guided by 
real time assessment of the cardiac output resulted in significant acute haemodynamic 
improvements [121].  
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Electrical latency appears a useful marker when looking to identify the optimal LV 
pacing site [19,20] and a similar approach can also be used when looking to optimise 
RV lead position. In the INTER-V study, the measurement of paced RV-LV interlead 
electrical delay predicted mid-term CRT response [122]. In a blinded, randomised 
controlled trial which prospectively allocated patients to receive CRT with either RV 
apical pacing or RV pacing at a site guided by maximal electrical separation (MES), 
individualised RV lead placement was associated with increased rates of 
echocardiographic response [123]. 
 
6.0 SITE SELECTION DURING LV ONLY PACING 
LV only pacing has also been proposed to avoid the negative sequelae associated with 
RV pacing by preserving intrinsic conduction via the right bundle branch. Different 
approaches to LV only pacing have been assessed for both epicardial and endocardial 
CRT. 
 
6.1 LV Only Epicardial Pacing 
Several comparative studies assessing LV only epicardial (LV EPI) pacing timed to 
coincide with intrinsic RV activation have been performed. LV EPI pacing has been 
shown to be associated with non-inferior outcomes [124–126], with some studies 
showing trends towards superior LV remodelling [127] and improvements in LVEF 
[128]. In all these studies, the LV lead was empirically placed in a lateral or 
posterolateral target vein and as such it is impossible to predict the implications of 
delivering LV EPI pacing at an alternative site. 
 
6.2 LV Only Endocardial Pacing 
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LV only endocardial (LV ENDO) pacing has also been investigated. Activation of the LV 
endocardium during CRT is associated with a reduction in both LV and biventricular 
(BiV) activation time [129]. This is in part explained by the shorter activation path length 
but also earlier activation of fast-conducting endocardial tissue, which possess a higher 
conduction velocity. LV ENDO pacing was associated with greater improvements in AHR 
than could be achieved using conventional, transvenous CRT (BiV EPI) [130]. Only 
biventricular endocardial CRT (BiV ENDO) proved capable of yielding a similar 
haemodynamic improvement.  
 
Much attention has been traditionally focussed on correcting the underlying 
electromechanical delay associated with LBBB by delivering LV stimulation at the site of 
latest activation, typically identified in the postero-lateral wall. An alternative approach is 
to try and replicate the activation sequence observed during normal sinus rhythm, 
where activation occurs initially at the left mid-septal endocardium [131,132]. When 
assessed, activation at this site results in an almost identical temporospatial activation 
envelope to that observed during normal sinus rhythm, especially when compared to 
BiV EPI, LV EPI and RV ENDO pacing [133]. This can be achieved via a transvenous 
approach, using a bespoke delivery mechanism incorporating a custom pacing lead 
which is introduced transvenously into the RV and positioned against the RV septum, 
before being deployed through the interventricular septum until the left ventricular 
septum is reached but without perforating the LV septum [134]. One major benefit of 
this approach is it negates the need for long-term anti-coagulation, typically associated 
with lead based LV ENDO pacing. 
LV ENDO septal pacing can achieve a haemodynamic performance similar to that 
observed during normal sinus rhythm in patients with preserved LV function [134]. The 
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effects of LV ENDO septal pacing have also been assessed in a small series of patients 
who fulfil current criteria for CRT implantation. A combination of RV ENDO and LV ENDO 
septal pacing achieved the greatest improvement in cardiac stroke work, suggesting 
that whilst the septum may represent a potential location to deliver stimulation in 
patients with impaired LV function, LV ENDO septal pacing alone may not be sufficient to 
achieve optimal resynchronisation [135]. 
 
 
7.0 MULTI-MODALITY IMAGING & IMAGE FUSION TECHNOLOGY 
7.1 Multi-Modality Imaging 
A novel approach to site selection incorporates the fusion of two differing imaging 
modalities via multi-modality imaging in order to maximise the reliability of the 
acquisition. Bertini et al describe an excellent approach aimed at targeting late 
mechanically activating, viable tissue [136]. Patients first underwent a CMR scan where 
areas the myocardial wall displaying of > 75% LGE were excluded. The next stage of 
the “CRT Team” approach involved the use of 2D speckle tracking echocardiography 
which assessed global LV longitudinal strain in order to highlight the most delayed area 
between non-fibrotic segments. The highest frequency of reverse remodelling at six 
months (93.1%) was observed in the 58% of patients where the final lead position was 
concordant with the prespecified optimal site [136]. 
Another novel approach employs the fusion of pre-procedural CMR imaging with 
computer modelling to predict the optimal pacing site. In this series, a 3D navigation 
model was designed to rank the available sites for LV and RV lead deployment. Sites 
were graded to ensure the LV lead was directed into the segment with the lowest scar 
burden which exhibited the greatest mechanical delay whilst also maximising the 
geographic distance between the LV and RV pacing sites. The RC lead tip was directed 
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to the area with lowest scar burden. The optimal location for the RV lead tip was 
assigned first followed by the preferential LV pacing site. At follow up, 74% of patients 
met the predefined echocardiographic criteria of a responder despite the fact that lead 
implantation was informed purely by fluoroscopy and visual assessment of the 3D 
models, and real time guidance was used [137].  
 
7.2 Image Fusion and Guidance Technology 
Optimal site selection can only be achieved when used in conjunction with a targeting 
system which can identify and inform pacing electrode deployment in real time during 
implantation. The use of fluoroscopy alone to facilitate targeted electrode deployment is 
challenging given the radiolucency of the cardiac silhouette and high variability in the 
rotation of the left and right sided chambers relative to one another. When previously 
evaluated, concordance between final fluoroscopic LV lead position & CT images was 
only observed in 35% of patients [138]. In over half of the cases studied, LV lead 
deployment had actually occured in an adjacent segment, although this is hardly 
surprising given the relatively small size of an individual myocardial segment (order of 
magnitude, cms). As such, site selection and X-Ray co-registration are essential in 
order to ensure optimal electrode deployment.    
 
7.3 Image Fusion with Fluoroscopic Coronary Sinus Balloon Venography 
Both the TARGET and STARTER studies showed the benefits of targeting lead 
deployment at the site of latest mechanical activation, defined using TTE [13,16]. 
Unfortunately, in the STARTER study, it was only possible to deploy the lead at the 
target segment in 30% of patients due to issues with coronary venous anatomy and 
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lead stability. Even in recent work where CMR was used to define the optimal pacing 
site, concordant LV lead positioning was only achieved in 52% of cases [93]. One 
approach to facilitate site selection at an achievable location subtended by a tributary of 
the coronary sinus is to evaluate both mechanical activation and coronary sinus 
anatomy. This can be achieved by fusing TTE derived 3D echo data with fluoroscopic 
coronary sinus balloon venography [14]. Use of this image guidance tool resulted in an 
LV reverse remodelling rate of 81% of patients, where concordance between final LV 
lead position and the site of LMA was confirmed. Whilst the use of coronary venous 
anatomy helps pre-procedural planning, this data was acquired via an additional 
invasive catheter study. 
 
A more streamlined approach fusing peri-procedural fluroscopic coronary sinus balloon 
venography with CMR imaging has also been developed [139], see Figure 3A. A major 
benefit of this system is the integrated nature of the GuideCRT platform (Siemens 
Healthineers, Erlangen, Germany). Image processing is automatic with manual 
verification. A quantitative analysis of late gadolinium enhancement is exported 
including information on scar location, burden and transmurality. In addition, regional 
motion analysis of volume vs. time is plotted via endocardial tracking for each of the 16 
myocardial segments, allowing identification of the latest activating region, see Figure 
3B. Image processing has now been accelerated to the stage (25 ± 8 mins) that the 
patient can undergo a CMR immediately prior to their CRT implant and by the time CS 
venography has been performed, image co-registration can be performed without delay.   
Nuclear perfusion imaging can also usefully delineate areas of viable (non-scared) 
myocardium which display late activation [140]. Again as coronary venous anatomy is 
not delineated on SPECT imaging, geometric alignment, landmark-based registration 
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and vessel-surface overlay were used to fuse the 3D venous anatomy with the 
epicardial mesh derived from the SPECT images [141], see Figure 4. 
 
7.3 Image Fusion and Guidance Technology Incorporating CT Derived Coronary 
Sinus Venography 
Whilst it is possible to visualise the coronary sinus using CMR [142], direct imaging of 
the sub-branches can be difficult to consistently achieve. CT however is capable of 
accurately delineating the coronary venous tree with submillimetre spatial resolution via 
rapid acquisition, 3D, isotropic, whole heart data sets [143]. Co-registration between 
pre-procedural CT derived volumetric datasets and intra-operative 2D image 
acquisitions is more straight forward and can be performed using both a feature-based 
and an intensity-based methods [144]. Work evaluating the use of dual-source CT to 
both inform site selection and identify an overlying tributary of the contrary sinus 
subtending this area is currently ongoing [145], see Figure 5. 
 
 
8. EXPERT COMMENTARY 
Transvenous, epicardial CRT remains the optimal therapy for those patients who exhibit 
a remediable underlying substrate and whose anatomy is amenable to allow adequate 
correction. The constraints of the CS anatomy have forced the exploration of novel 
means or performing resynchronisation pacing and of these endocardial CRT holds the 
most promise. Endocardial LV pacing results in a more physiological, endocardial to 
epicardial activation pattern, a greater reduction in total LV activation time (LVTAT) and 
an improved haemodynamic performance (greater increases in LV dP/dtmax ) in both the 
LV [129,146] and RV [147]. It is also associated with a higher implant success rates, 
less phrenic nerve stimulation and far greater access to different pacing sites. The 
 
26 
optimal LV endocardial pacing site displays marked inter and intra-patient variability and 
whilst some argue that any endocardial pacing site will invariably prove superior to 
epicardial stimulation, research has shown that sub-optimal BiV ENDO CRT can achieve 
haemodynamic improvements inferior to those associated with empirically positioned 
BiV EPI CRT [100]. As such, whilst endocardial pacing affords the freedom to perform LV 
stimulation at a customisable location, site selection is even more critical in order to 
maximise the potential benefits associated with this technique.  
 
Tissue characterisation remains an integral parameter when looking to optimise CRT 
delivery. Targeting viable tissue is clearly beneficial and this can be achieved using a 
variety of modalities. Undertaking a direct head-to-head comparison of these diagnostic 
approaches would aid the development off future LV lead guidance systems. Whilst it is 
clear targeting viable myocardium is beneficial, it remains to be seen precisely how the 
presence of discrete areas of scar affects the location of the optimal pacing site.  
Assessing mechanical dyssynchrony can also be achieved through a variety of 
modalities however, the prospective evidence proving dyssynchrony assessments can 
improve patient selection for CRT is lacking [86,87]. The use of CMR based 
dyssynchrony indexes may offer a more reliable solution [18], however larger scale, 
prospective, randomised validation of these techniques is required before they can be 
comprehensively endorsed. In the mean-time, mechanical dyssynchrony assessments 
aimed at identifying viable sites exhibiting late mechanical activation do appear to aid 
LV site selection. It’s not clear whether this approach is superior to targeting sites of 
electrical latency or even whether these two sites are synonymous [112]. Both Q-LV 
[19] and LVLED [20] appear particularly useful markers to aid site selection. Neither 
technique requires sophisticated electro-anatomical mapping or additional pre-
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procedural image processing and instead can be calculated by the operator at the time 
of LV lead deployment. A more integrated approach is likely to be necessary however, 
than simply targeting the site of latest electrical activation, particularly in ischaemic 
patients. Instead, the focus should be on targeting a site which displays late activation 
in the absence of myocardial scar. Narrowing of the paced QRS during pacing appears 
a less reliable marker of the optimal pacing site and we would urge caution with this 
approach given the potential for electro-mechanical uncoupling. Optimising the RV 
pacing site by identifying electrical delay also appears to beneficial [123], especially 
when revising a previously implanted system where the position of the LV lead is 
relatively fixed.  
Another novel approach to CRT involves attempting to selectively capture the His-
Purkinji network of fast conducting fibres via LV only pacing. Rather than trying correct 
underlying electro-mechanical dyssynchrony, this approach aims to replicate healthy 
intrinsic biventricular depolarisation. New delivery mechanisms allow stimulation of the 
LV septum via trans-venous access [134] meaning this approach may well become 
increasingly widespread. Whether similar results can be achieved through selective His 
capture in the RV remains to be seen, although initial studies of this promising pacing 
modality appear promising [148].  
Site selection remains only as good as the adjunctive guidance system given the 
technical limitations of spatial orientation using conventional fluoroscopy [138]. Co-
registration between 2D and 3D modalities is challenging with the simplest solution 
integrating pre-implant imaging data with peri-procedural coronary sinus balloon 
venography. However, these systems are unable to determine whether a suitable 
tributary of the coronary sinus subtends the target segment until the procedure has 
begun highlighting a limitation of the transvenous, epicardial CRT. Guidance systems 
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which can accurately visualise the entire coronary sinus network pre-procedurally, allow 
decisions to made regarding not just the most appropriate target but also the most 
suitable means of targeting this area. 
9. FIVE YEAR VIEW 
Transvenous epicardial CRT will continue to function as the default strategy for the 
delivery of CRT. Pre-procedural imaging and modelling [149] will however, allow 
physicians to identify those patients who may benefit from an alternative pacing 
strategy; either due to a lack of suitable targets or recognition that the target area 
cannot be accessed via the epicardial coronary venous system. More widespread 
recognition of cases where this is the case will result in greater use of endocardial 
pacing, and in particular leadless endocardial pacing systems such as the WiSE-CRT 
system (WiSE-CRT System, EBR Systems, Sunnyvale, California) which have proved 
safe and effective and do not require long-term anticoagulation [150]. Growth in 
endocardial pacing will mandate increasing use of site selection and guidance given the 
optimal LV endocardial pacing displays such a high degree of variability.  
The WiSE-CRT system has been developed with trans-femoral arterial access in mind, 
however, arterial access complications remain an issue and given the EP community’s 
familiarity with trans-septal access, trans-venous access [151] will become increasingly 
de rigour. In addition, entire pacing systems will likely become leadless with atrial and 
right ventricular activation coordinated via communication between the various 
components.  
CMR remains the pre-eminent imaging modality for assessing both tissue 
characterisation and mechanical activation and increasing experience with ultrahigh 
field CMR will inevitably result in improved image quality [152,153]. Greater spatial 
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resolution will allow detailed visualisation of the entire coronary venous tree allowing 
pre-procedural planning to be performed entirely from one, non-ionising imaging 
modality.  
Other non-invasive imaging techniques which may become increasingly adopted are 
electrocardiographic imaging & Holographic imaging systems. ECGi allows an 
assessment of tissue characterisation and can be used to locate areas exhibiting late 
electrical activation. Refinement of body surface mapping systems now means that 
instead of multiple electrode vests, a more straightforward ECG belt [154] can derive 
information on local electrical delay in order to guide LV lead implantation. Holographic 
imaging systems like the Holoscope (Real View Imaging, Yokneam, Israel) allow users 
to interact directly with a live 3D digital hologram. Physicians can manipulate the image 
(rotating, slicing, measuring and marking) [155] fostering a greater understanding of the 
patients own unique anatomy. 
 
10. KEY ISSUES 
• Transvenous, epicardial CRT remains an excellent therapy for those patents with 
right substrate and the right anatomy allowing this substrate to be corrected. 
• The constraints of CS anatomy have forced the exploration of novel means of 
performing CRT and of these endocardial CRT holds the most promise. 
• Endocardial CRT has several advantages over epicardial CRT, but the optimal 
endocardial site displays marked variability and in order to maximise benefits, 
site selection is critical. 
• Assessment of tissue characterisation is essential as viable myocardium should 
always be targeted. This can be achieved in a number of different ways.  
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• There is conflicting evidence as to whether an assessment of mechanical 
dyssynchrony can aid in patient selection for CRT over and above current 
guideline indications however, targeting sites exhibiting late mechanical 
activation appears useful. 
• Targeting late electrical activation also appears a promising strategy. Q-LV and 
LVLED appear very useful when looking to identify the optimal site. The site of 
latest activation is not consistently associated with the optimal haemodyanamic 
improvement. Instead a position which displays late but not excessively late 
activation appears the most beneficial.  
• Narrowing of the QRS during pacing appears a less reliable marker of the 
optimal pacing site. 
• Optimising the RV pacing site may be of benefit, especially when revising a 
previously implanted system where the position of the LV lead is relatively fixed. 
• LV only pacing appears promising, particularly in those with preserved LV 
function. New delivery technology means both of these systems can be 
implanted transvenously.   
• Site selection is only as good as the adjunctive guidance system. Guidance 
systems which integrate pre-procedural imaging with peri-procedural coronary 
sinus balloon venograpghy are unable to determine whether a suitable tributary 
of the CS subtends the target segment until the procedure has begun. This is a 
limitation of the transvenous epicardial approach. Systems which can directly 
visualise the CS during pre-procedural planning allow decisions to made 
regarding the most suitable method of targeting this area. 
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FIGURE TITLES AND LEGENDS: 
Figure 1. The 252-lead vest records torso surface electrograms. Reproduced with 
permission from MEDTRONIC. 
Figure 2. Comparison of sites of LEA (A) and LMA (B). The circled numbers refer to the 
patient numbers. Reproduced with permission from Pacing and Clinical 
Electrophysiology 
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Figure 3A. (Top left) Anteroposterior venogram with overlay of CMR-derived 
epicardial/endocardial shell with 16-segment American Heart Association model 
showing an anterior interventricular vein. The 3D CMR-derived shell has the same 
colours as displayed in the guidance platform as shown in Figures 2 and 3. Infero-
septal, antero-septal, and anterior segments are coloured in yellow, green, and blue, 
respectively. (Top right) left anterior oblique (LAO) 20 venogram with automated 
rotation and alignment of the 16-segment model with the x-ray. Inferolateral veins are 
demonstrated. (Bottom left) LAO 40 projection. Positioning of a quadripolar left 
ventricular lead into a preselected target segment (green). (Bottom right) LAO 40 
projection, alternate view with CMR-derived scar distribution (red). Attempted 
positioning and pacing using left ventricular poles out of regions of scar. [139] 
Reproduced with permission due to the creative commons license. 
 
Figure 3B. This display screen is seen following the processing of the CMR dataset 
and is mimicked on the large screen in the catheter laboratory. Total scar burden 
calculated as a mean of all myocardial segments. (Top middle) Scar distribution 
denoted in grey upon an American Heart Association 16-segment model. (Top right) 
Scar burden (% scar per myocardial segment volume), displayed in 5% ranges. (Bottom 
right) Scar transmurality demonstrating the mean transmurality from endocardium to 
epicardium. Those segments >50% transmural myocardial fibrosis are also denoted in 
red. (Bottom left) Mechanical activation curves for the 16 segments, corresponding to 
the colours shown in the middle panels. Endocardial tracking of the left ventricle 
provides absolute changes in the volume per segment (ml, y axis) over the cardiac 
cycle (0% end diastole, 30% to 50% end systole, 100% end diastole). Because these 
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are absolute volume changes, the apical segments are always at the bottom because 
they have a smaller start and end volume. When the user hovers over a segment in the 
top middle panel, the associated volume time curve appears in bold; in this case, the 
target posterolateral segment is shown. (Bottom middle) Target selection panel. Upon 
reviewing the scar location, burden, transmurality, and mechanical activation curves, 
target segments are chosen (seen here in white; basal anterior, mid-posterolateral). 
EDV 1⁄4 end-diastolic volume; EF 1⁄4 ejection fraction; ESV 1⁄4 end-systolic volume; 
SDI 1⁄4 systolic dyssynchrony using endocardial tracking of CMR cine images in short 
and long axis;  Reproduced with permission due to the creative commons license. [139]. 
 
Figure 4. (A) Target venous site for LV lead placement. Major LV veins were drawn on 
fluoroscopic venograms, reconstructed to a 3D structure, and fused with SPECT LV 
epicardial surface. The mid part of AV (blue line) was aligned with the optimal segment 
(white segment) and so was targeted for lead placement. (B) Post-implant fluoroscopy. 
The LV lead was placed using the guidance in (A). The post-implant images show that 
the LV lead (red arrows) was on target. (C) Post-implant electrocardiogram. The QRS 
duration decreased from 168 to 140 ms immediately after the cardiac resynchronization 
therapy (CRT) device was turned on. RAO 1⁄4 right anterior oblique. Reproduced with 
permission from JACC: Cardiovascular Imaging [141] 
 
Figure 5. Series of DECCT-derived scar and image overlay of the coronary sinus and 
optimal target segment derived from CT strain measurements from one patient: 
Retrospective CCT demonstrating calcification in a Left Anterior Descending (LAD) and 
circumflex territory infarct (A). Dual energy CCT demonstrating subtle ventricular scar in 
the LAD and circumflex territory (B). Late iodinated enhancement plotted on American 
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Heart Association (AHA) 17 segment bull's-eye plot suggesting scar in the LAD and 
circumflex territory but also artefact from an existing RV pacing lead in the basal to mid 
antero-septum (C). First pass iodine uptake plotted on an AHA 17 segment bull's-eye 
plot showing what we believe to be residual iodine predominately in the LAD and 
circumflex territory (D). CCT-derived dyssynchrony curves calculated by myocardial 
strain (E). Cardiac magnetic resonance short axis image of the mid LV showing late 
gadolinium enhancement of the same patient taken two years prior to any device 
implantation for comparison purposes (F). Pre-procedure DECCT-derived coronary 
sinus segmentation fused with latest mechanical activating segments determined from 
DECCT-derived strain (G) co-registered and overlaid onto live fluoroscopy using fusion 
software (H).[145] 
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